skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The role of insulin detemir in overweight type 2 diabetes management

Review

(3710) Views  (945) Full article downloads

Authors: Yared N Demssie, Naveed Younis, Handrean Soran

Published Date June 2009 Volume 2009:5 Pages 553 - 560
DOI: http://dx.doi.org/10.2147/VHRM.S4326

Yared N Demssie1, Naveed Younis2, Handrean Soran3

1Department of Diabetes and Endocrinology, Salford Royal Foundation NHS Trust, Salford, UK; 2Department of Medicine, University Hospital South Manchester Foundation NHS Trust, Wythenshawe, Manchester, UK; 3University Department of Medicine, Central Manchester and Manchester Children’s NHS Foundation Trust, Manchester, UK

Abstract: The recent evidence-based shift towards an algorithm of early initiation and aggressive titration of insulin therapy in the management of type 2 diabetes requires the use of an effective insulin formulation that is both safe and acceptable to patients and physicians alike. The advent of the long-acting insulin analogues, insulin detemir and glargine, in the last decade has revolutionized insulin therapy in type 2 diabetes. Their unique pharmacokinetic and pharmacodynamic properties have offered tangible advantage over the conventional intermediate and long-acting insulin preparations in terms of improving glucose control as well as reducing risk of hypoglycemia and weight gain. This review focuses on the pharmacodynamic properties of the long-acting insulin analogue detemir, the outcome of studies on its relative efficacy and safety as well as its proposed place in the management of type 2 diabetes.

Keywords: insulin detemir, type 2 diabetes, overweight








Readers of this article also read:

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Prognostic stratification of acute pulmonary embolism: Focus on clinical aspects, imaging, and biomarkers
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog
Cardiac risk stratification: Role of the coronary calcium score
Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
Adverse drug reaction suggests by a clinical vignette
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University